Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
Conditions: NSCLC Stage IV; NSCLC Stage IIIB Intervention: Drug: Ipatasertib Sponsors: University of Kansas Medical Center; University of Iowa; University of Kentucky Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials